BMS files legal challenge to HHS' 340B rebate decision
Bristol-Myers Squibb has become the latest pharma in the US to file a legal challenge to a block on a 340B drug rebate model opposed by HRSA.
Newsletters and Deep Dive digital magazine
Bristol-Myers Squibb has become the latest pharma in the US to file a legal challenge to a block on a 340B drug rebate model opposed by HRSA.
The journey to global market access for innovative therapies is fraught with challenges that vary significantly across the world.
The outlook for drug development to treat rare diseases looks encouraging, offering hope to the 300 million people globally facing the significant challenges of these often-overlooked condi
Sanofi has officially opened a modular biologics manufacturing facility in Singapore that is designed to allow rapid switching between products
Kelun-Biotech has become the second drugmaker to bring a TROP2 ADC to regulatory approval, after its sac-TMT drug was cleared in China
Editor's Picks
Newsletters and Deep Dive
digital magazine